Advertisement

Strategies for Improving the Efficiency of Long-Term Intervention Studies

  • Michael Gent
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 39)

Abstract

A number of major trials 1–10 evaluating various platelet suppressing drugs in the secondary prevention of myocardial infarction and cerebral ischemia have come to a close over the past two or three years (see Table 1). It had been the hope of many that promising drugs such as sulfinpyrazone, aspirin and dipyridamole would by now have been clearly shown to be of benefit and thus would have a considerable impact on two of the three major causes of death in the western world. Failing this, it might have been hoped they would have been shown to be of no value and hence efforts could have been redirected to other opportunities.

Keywords

Cerebra1 Ischemia Arteriovenous Shunt Abnormal Rhythm Study Research Group Coronary Drug Project 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    P.C. Elwood, A.L. Cochrane, M.L. Burr, P.M. Sweetnam, G. Williams, E. Welsby, S.J. Hughes and R. Renton, A randomized controlled clinical trial of acetel salicylxc acid in the secondary prevention of mortality from myocardial infarction, Br Med J. 1: 436 (1974)PubMedCrossRefGoogle Scholar
  2. 2.
    The Coronary Drug Project Research Group, Aspirin in coronary heart disease, J Chronic Dis. 29: 625 (1976)CrossRefGoogle Scholar
  3. 3.
    The Anturane Reinfarction Trial Research Group, Sulfinpyrazone in the prevention of cardiac death after myocardial infarction: the Anturane Reinfarction Trial, N Engl J Med. 298: 289 (1978)CrossRefGoogle Scholar
  4. 4.
    The Anturane Reinfarction Trial Research Group, Sulfinpyrazone in the prevention of sudden death after myocardial infarction, N Engl J Med. 302: 250 (1980)CrossRefGoogle Scholar
  5. 5.
    K. Breddin, Multicenter two-years prospective study on the prevention of secondary myocardial infarction by ASA in comparison with phenprocoumon and placebo, in “Essais controles multicentres principes et problemes”, edited by J.P. Boissel, C.R. Klimt, eds., I.N.S.E.R.M., Paris (1979)Google Scholar
  6. 6.
    P.C. Elwood and P.M. Sweetnam, Aspirin and secondary mortality after myocardial infarction, Lancet, ii: 1313 (1979)Google Scholar
  7. 7.
    Aspirin Myocardial Infarction Study Research Group, A randomized controlled trial of aspirin in persons recovered from myocardial infarction, JAMA. 243: 661 (1980)CrossRefGoogle Scholar
  8. 8.
    The Persantine - Aspirin Reinfarction Study Research Group, Persantine and aspirin in coronary heart disease, Circulation. 62: 449 (1980)CrossRefGoogle Scholar
  9. 9.
    W.S. Fields, N.A. Lemak, R.F. Frankowski and R.J. Hardy, Controlled trial of aspirin in cerebral ischemia, Stroke. 8: 301 (1977)PubMedCrossRefGoogle Scholar
  10. 10.
    Canadian Cooperative Study Group, A randomized trial of aspirin and sulfinpyrazone in threatened stroke, N Engl J Med. 299: 53 (1978)CrossRefGoogle Scholar
  11. 11.
    Genton, M. Gent, J. Hirsh and L.A. Harker, Platelet-inhibiting drugs in the prevention of clinical thombotic disease, N Engl J Med. 293: 1174, 1236, 1296 (1975)CrossRefGoogle Scholar
  12. 12.
    E. Genton, H.J.M. Barrxett, W.S. Fields, M. Gent and J.C. Hoak (Study Group on Antithrombotic Therapy), Cerebral ischemia: The role of thrombosis and antithrombotic therapy, Stroke. 8: 148 (1977)CrossRefGoogle Scholar
  13. 13.
    D.L. Sackett, Design, measurement and analysis in clinical trials, in “Platelets, Drugs and Thrombosis”, J. Hirsh, J.F. Cade, A.S. Gallus and E. Schonbaum, eds., S Karger, Basel (1975)Google Scholar
  14. 14.
    J.R. Harnes, Sulfinpyrazone after myocardial infarction, N Engl J Med. 298: 1258 (1978)Google Scholar
  15. 15.
    S. Sherry, M. Gent, J.F. Mustard, M. McGregor, A. Lilienfeld and P. Yu, Sulfinpyrazone after myocardial infarction (C), N Engl J Med. 29. 8: 1259 (1978)Google Scholar
  16. 16.
    D.W. Evans, Anturane Reinfarction Trial (C), Lancet, ii: 366 (1978)Google Scholar
  17. 17.
    Editorial, Sulfinpyrazone and prevention of myocardial infarction, FDA Drug Bull. 8: 3 (1978)Google Scholar
  18. 18.
    Editorial, Sulfinpyrazone and prevention of myocardial infarction, and the prevention of death: a successful trial or another tribulation?, Br Med J. 1: 941 (1978)Google Scholar
  19. 19.
    Editorial, FDA says no to Anturane, Science. 208: 1130 (1980)CrossRefGoogle Scholar
  20. 20.
    J.D. Whisnant, The Canadian trial of aspirin and sulfinpyrazone in threatened stroke (C). N Engl J Med. 299: 953 (1978)CrossRefGoogle Scholar
  21. 21.
    J.E. Thompson, The Canadian trial of aspirin and sulfinpyrazone * in threatened stroke (C), N Engl J Med. 299: 954 (1978)Google Scholar
  22. 22.
    D.L. Sackett, The Canadian trial of aspirin and sulfinpyrazone in threatened stroke (C), N Engl J Med. 299: 955 (1978)Google Scholar
  23. 23.
    J.F. Kurtzke, Controversy in neurology: the Canadian study on TIA and aspirin. A critique of the Canadian TIA study (C), Ann Neurol. 5: 597 (1979)PubMedCrossRefGoogle Scholar
  24. 24.
    H.J.M. Barnett, M. Gent, D.L. Sackett and D.W. Taylor, Controversy in neurology: the Canadian study on TIA and aspirin. A critique of the Canadian TIA study. Reply (C), Ann Neurol. 5: 599 (1979)PubMedCrossRefGoogle Scholar
  25. 25.
    P. Armitage, Controversy in the interpretation of clinical trials, Ann Neurol. 5: 601 (1979)PubMedCrossRefGoogle Scholar
  26. 26.
    A.M. Lilienfeld, Critique of “A randomized trial of aspirin and sulfinpyrazone in threatened stroke”, in “Cerebrovascular Diseases”, T.R. Price and E. Nelson, eds., Raven Press, New York (1979)Google Scholar
  27. 27.
    J.F. Kurtzke, Critique of the Canadian “TIA” study, in “Cerebrovascular Diseases”, T.R. Price and E. Nelson, eds., Raven Press, New York (1979)Google Scholar
  28. 28.
    C.H. Millikan, Does taking aspirin prevent stroke in the general population, TIA patients, completed stroke patients?, in “Drug Treatment and Prevention in Cerebrovascular Disorders”, G. Tognoni and S. Garattini eds., Elsevier/North-Holland Biomedical Press, Amsterdam (1979)Google Scholar
  29. 29.
    M. Gent, Recent intervention studies of platelet suppressant drugs in cerebral ischemia: Methodological aspects, in “Drug Treatment and Prevention in Cerebrovascular Disorders”, G. Tognoni and S. Garattini eds., Elsevier/North-Holland Biomedical Press, Amsterdam (1979)Google Scholar
  30. 30.
    J.F. Whisnant, The Canadian trial of aspirin and sulfinpyrazone in threatened stroke, Am Heart J. 99: 129 (1980)PubMedCrossRefGoogle Scholar
  31. 31.
    P. Armitage, Trials of antiplatelet drugs, some methodological considerations, Rev epidem et sante publ. 27: 87 (1979)Google Scholar
  32. 32.
    M. Gent and D.L. Sackett, The qualification and disqualification of patients and events in long term cardiovascular clinical trials, Thromb Hemostas. 41: 123 (1979)Google Scholar
  33. 33.
    D.L. Sackett and M. Gent, Controversy in counting and attrib-uting events in clinical trials, N Engl J Med. 301: 1410 (1979)PubMedCrossRefGoogle Scholar
  34. 34.
    D. Schwartz and J. Lellouch, Explanatory and pragmatic attitudes in therapeutic trials, J Chronic Dis. 20: 637 (1967)PubMedCrossRefGoogle Scholar
  35. 35.
    R. Peto, M.C. Pike, P. Armitage, N.E. Breslow, D.R. Cox, S.V. Howard, N. Mantel, K. McPherson, J. Peto and P.G. Smith, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I: Introduction and design, Br J Cancer. 34: 585 (1976)PubMedCrossRefGoogle Scholar
  36. 36.
    R. Peto, M.C. Pike, P. Armitage, N.E. Breslow, D.R. Cox, S.V. Howard, N. Mantel, K. McPherson, J. Peto and P.G, Smith, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: Analysis and examples, Br J Cancer. 35: 1 (1977)PubMedCrossRefGoogle Scholar
  37. 37.
    T.L. Simon, J.H. Ware and J.M. Stengle, Clinical trials of thrombolytic agents in myocardial infarction, Am Int Med. 79: 712 (1973)Google Scholar
  38. 38.
    A. Kaegi, G.F. Pineo, A.G. Shimizu, H. Trivedi, J. Hirsh and M. Gent, The role of sulfinpyrazone in the prevention of arteriovenous shunt thrombosis, Circulation. 52: 497 (1975)PubMedCrossRefGoogle Scholar
  39. 39.
    Multicentre International Study, Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade, Br Med J. 2: 419 (1977)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1981

Authors and Affiliations

  • Michael Gent
    • 1
  1. 1.Faculty of Health SciencesMcMaster UniversityHamiltonCanada

Personalised recommendations